Ozempic is officially a diabetes medication. The FDA approved it in 2017 specifically for adults with type 2 diabetes, and it has never been approved for weight loss. But the same active ingredient, semaglutide, is sold under a different brand name (Wegovy) for weight management, and roughly 30% of Ozempic prescriptions are now written off-label for obesity-related conditions. So the short answer is: it’s approved for diabetes, widely used for both.
What Ozempic Is Approved to Treat
Ozempic carries three FDA-approved uses, all tied to type 2 diabetes. It can be prescribed alongside diet and exercise to lower blood sugar, to reduce the risk of heart attack, stroke, and cardiovascular death in people with type 2 diabetes and heart disease, and to protect kidney function in people with type 2 diabetes and chronic kidney disease. Weight loss is not listed anywhere on its label.
Wegovy, by contrast, contains the exact same drug at a slightly higher maximum dose (2.4 mg versus Ozempic’s 2 mg per week) and is FDA-approved for weight management in adults and children 12 and older. It also has separate approvals for reducing cardiovascular risk in people with obesity or overweight who have heart disease, and for treating a form of fatty liver disease. The two products come from the same manufacturer, use the same injection device, and work identically in the body. The distinction is regulatory, not chemical.
Why Doctors Prescribe It for Weight Loss Anyway
Off-label prescribing is legal and common across medicine. A doctor can prescribe any FDA-approved drug for a condition it wasn’t specifically approved for if they believe the evidence supports it. With Ozempic, the evidence is hard to ignore: semaglutide produces significant weight loss in clinical trials, and Wegovy’s approval confirmed the drug works for that purpose. Ozempic’s off-label use for obesity jumped from about 22% of its prescriptions in 2018 to roughly 30% by 2023, driven largely by nurse practitioners and primary care physicians treating patients with obesity-related conditions.
There are practical reasons for this pattern. Wegovy has faced persistent supply shortages. Some insurance plans cover Ozempic for diabetes but won’t cover Wegovy for weight loss. And for patients who have both type 2 diabetes and excess weight, Ozempic handles both problems with a single weekly injection.
How It Works in the Body
Semaglutide mimics a hormone your gut naturally releases after eating called GLP-1. This hormone does two things that matter here, and they explain why the same drug treats both conditions.
For blood sugar: GLP-1 tells your pancreas to release more insulin when glucose levels rise, while also suppressing glucagon, the hormone that tells your liver to dump stored sugar into the bloodstream. The result is tighter blood sugar control without the dangerous lows that older diabetes medications can cause, because the insulin boost only kicks in when blood sugar is actually elevated. Semaglutide also supports the health and growth of the insulin-producing cells in the pancreas.
For weight: GLP-1 acts on appetite centers in the brain, increasing feelings of fullness and reducing hunger. It also slows how quickly food leaves your stomach, so you feel satisfied longer after meals. These effects aren’t a side benefit. They’re a core part of what GLP-1 does in the body. People on Ozempic eat less because they genuinely want less food, not because they’re forcing restriction.
How Well It Works for Diabetes
In real-world data from over 1,700 patients with type 2 diabetes, Ozempic at the 1 mg weekly dose lowered HbA1c (a measure of average blood sugar over three months) by 1.2 percentage points. Patients who stayed on the medication consistently saw a larger drop of 1.4 points, and more than 56% of those patients achieved at least a one-point reduction. For context, a one-point drop in HbA1c is considered clinically meaningful and is associated with significantly lower risk of diabetes complications like nerve damage, kidney disease, and vision loss.
Insurance Coverage Differs by Diagnosis
This is where the “diabetes or weight loss” distinction has real financial consequences. Most insurance plans, including Medicare Part D, cover Ozempic when prescribed for type 2 diabetes. Medicare Part D currently excludes medications used solely for weight loss under a longstanding statutory rule, though regulators have proposed changing this policy.
Wegovy was initially excluded from Medicare coverage entirely. That changed in March 2024 when it received an additional approval for cardiovascular risk reduction in people with obesity or overweight and heart disease, giving Medicare a non-weight-loss reason to cover it. For people without diabetes who want semaglutide purely for weight management, coverage remains inconsistent. Many commercial plans cover Wegovy, but copays and prior authorization requirements vary widely. Some patients end up seeking Ozempic prescriptions because their insurance formulary makes it more accessible, even when weight loss is their primary goal.
Dosing and What to Expect
Ozempic is a once-weekly injection you give yourself, typically in the stomach, thigh, or upper arm. The starting dose is 0.25 mg per week for the first four weeks, which is a “getting used to it” dose not expected to produce full therapeutic effects. At week five, the dose increases to 0.5 mg. From there, your doctor may raise it to 1 mg or eventually 2 mg depending on your response and goals. The gradual increase exists to minimize side effects.
Nausea is the most common issue, affecting 15% to 23% of patients. Diarrhea occurs in 8% to 14%. Both tend to be worst during dose increases and improve over time as your body adjusts. Eating smaller meals, avoiding greasy or heavy foods, and not lying down right after eating can help manage the nausea in the early weeks.
Ozempic vs. Wegovy: Which One You’d Get
If you have type 2 diabetes, your doctor will likely prescribe Ozempic (or its oral form, Rybelsus). If you don’t have diabetes and your primary concern is weight, the appropriate prescription is Wegovy, assuming it’s available and your insurance covers it. Both are semaglutide. Both cause weight loss. Both improve metabolic health. The main differences are the approved indications, the maximum dose (Wegovy goes slightly higher), and how insurance handles them.
If you have type 2 diabetes and want to lose weight, Ozempic addresses both simultaneously, and your doctor doesn’t need to justify the weight loss component to your insurer because the diabetes indication alone supports the prescription. This overlap is a big part of why Ozempic became so widely associated with weight loss even though it’s technically a diabetes drug.